Roughly one out of every five adults suffers from sleep-disordered breathing. Left untreated, this condition can greatly increase a patient’s chance of developing diabetes, heart disease, obesity, and more. Decades ago, ResMed (NYSE: RMD) pioneered a treatment called continuous positive airway pressure, or CPAP, which utilizes a pump and mask to keep a patient’s airway open during the night. ResMed’s sales and profits have consistently grown ever since. Coming into Monday night’s earnings report, investors were expecting more of the same.